

Datasheet for ABIN234815

anti-Botulinum Neurotoxin Type B (BoNT/B) (AA 1278-1291), (C-Term) antibody



Go to Product page

| _ | | | | | |
|---|---|---|----|----|---|
| | W | 0 | rv | 10 | W |

| Quantity: | 1 mL | |
|---|---|--|
| Target: | Botulinum Neurotoxin Type B (BoNT/B) | |
| Binding Specificity: | AA 1278-1291, C-Term | |
| Reactivity: | Clostridium botulinum | |
| Host: | Mouse | |
| Clonality: | Monoclonal | |
| Conjugate: | Un-conjugated | |
| Application: | ELISA, Radioimmunoassay (RIA), Indirect Immunofluorescence Assay (IFA) | |
| Product Details | | |
| Immunogen: | Synthetic peptide analogue of the carboxyl terminal region of C. botulinum Toxin B (Catalog ABIN573256) | |
| Clone: | B362M | |
| Isotype: | IgG | |
| | Binds to intact whole C. botulinum Toxin B, amino acids 1278-1291. Has been found to stain Neuro2A cells treated with GT1b ganglioside prior to the addition of C. botulinum Toxin B. Inhibits the entry of C. botulinum Toxin B to Neuro2A cells treated with GT1b ganglioside prior to the addition of the toxin. | |
| Specificity: | Neuro2A cells treated with GT1b ganglioside prior to the addition of C. botulinum Toxin B. Inhibits the entry of C. botulinum Toxin B to Neuro2A cells treated with GT1b ganglioside prior | |
| Specificity: Cross-Reactivity (Details): | Neuro2A cells treated with GT1b ganglioside prior to the addition of C. botulinum Toxin B. Inhibits the entry of C. botulinum Toxin B to Neuro2A cells treated with GT1b ganglioside prior | |

| Product Details | | |
|---------------------|--|--|
| Characteristics: | MAb to C. botulinum Toxin B, Monoclonal antibody to Clostridium botulinum Toxin B (AA 1278-1291) | |
| Purification: | Protein A column. Ascites | |
| Target Details | | |
| Target: | Botulinum Neurotoxin Type B (BoNT/B) | |
| Alternative Name: | Clostridium Botulinum Toxin B (BoNT/B Products) | |
| Application Details | | |
| Application Notes: | Suitable for use in ELISA, IFA and RIA. Suitable for use in an indirect immunocytochemical staining procedure at a dilution of 1:25. Prior incubation of the antibody with synthetic peptide immunogen has been shown to eliminate the inhibition of cellular binding by the antibody. Each laboratory should determine an optimum working titer for use in its particular application. Other applications have not been tested but use in such assays should not necessarily be excluded. | |
| Restrictions: | For Research Use only | |
| Handling | | |
| Format: | Liquid | |
| Preservative: | Without preservative | |
| Handling Advice: | Avoid multiple freeze/thaw cycles. Centrifuge product if not completely clear after standing at room temperature. Prepare working dilution only prior to immediate use. | |
| Storage: | -20 °C | |

Upon receipt, store at -20 °C.

Storage Comment: